EVO ICL is an implantable lens that’s placed inside your eye to correct nearsightedness, working like a permanent contact lens you never have to remove or maintain. Unlike LASIK, which reshapes your cornea with a laser, EVO ICL leaves your cornea completely untouched. The lens sits behind your iris and in front of your natural lens, correcting vision for prescriptions ranging from -3.0 to -20.0 diopters. It’s FDA-approved for adults between 21 and 45 years old.
How the Lens Works
The “ICL” stands for Implantable Collamer Lens. Collamer is a proprietary material made from a blend of a soft polymer and purified collagen. Because it contains collagen, a protein your body already produces, the lens is highly biocompatible. Your immune system doesn’t recognize it as a foreign object, so inflammation and rejection are rare. The material also filters ultraviolet light, adding a layer of protection for your eye.
What sets the EVO version apart from earlier implantable lenses is a small central port built into the lens. This tiny opening allows fluid to flow naturally between the front and back chambers of your eye. Older versions of the lens blocked this flow, which meant surgeons had to create a separate hole in the iris (called a peripheral iridotomy) before implanting the lens. The central port eliminated that extra step, simplifying the procedure and reducing the risk of pressure buildup inside the eye.
Who Is a Good Candidate
EVO ICL is designed for moderate to high nearsightedness. The FDA approval covers correction of prescriptions from -3.0 to -15.0 diopters and reduction of prescriptions from -15.0 to -20.0 diopters. A toric version (called the EVO TICL) can also correct astigmatism between 1.0 and 4.0 diopters. Your eye needs to have an anterior chamber depth of at least 3.0 millimeters, which your surgeon measures during the pre-operative evaluation.
The procedure is particularly well suited for people who aren’t candidates for LASIK. If you have thin corneas, for example, LASIK may not be safe because it requires removing corneal tissue to reshape your eye. EVO ICL has no minimum corneal thickness requirement. It’s also a strong option if you have chronic dry eyes, since corneal procedures like LASIK can worsen dryness by disrupting the nerves in the cornea. EVO ICL carries a lower risk of triggering or worsening dry eye syndrome because it doesn’t alter the corneal surface at all.
The Procedure and Recovery
The surgery itself is quick. Your surgeon makes a tiny incision at the edge of the cornea, folds the soft lens, inserts it through the opening, and positions it behind the iris. The incision is small enough that it typically self-seals without stitches. The procedure is done one eye at a time, usually with the second eye treated a few days to a week later.
Most people notice improved vision almost immediately, though things may look a bit hazy for the first day or two. During the first week, your vision should start to stabilize. Full stabilization, where your prescription settles to its final result, can take a few months. You’ll have several follow-up visits during this period so your surgeon can check the lens position and measure the pressure inside your eye.
Visual Outcomes
Results from the FDA’s three-year prospective clinical study of EVO ICL are strong. At the three-year mark, 85.8% of eyes achieved 20/20 vision or better without glasses or contacts. More than half (54.9%) reached 20/16 or better, which is sharper than standard “perfect” vision. Nearly all eyes in the study, 99.5%, achieved at least 20/40, the threshold for legal driving without correction in most states.
Long-Term Safety and Risks
The most significant long-term risk is cataract formation. A ten-year follow-up study of patients with high myopia found that cataracts developed in about 20% of eyes by year ten. This is worth putting in context: people with high myopia are already at elevated risk for earlier cataracts regardless of whether they have any surgery. If a cataract does develop, the ICL can be removed and standard cataract surgery performed at the same time.
Glaucoma is rare. In that same long-term study, it occurred in just 1.5% of eyes. Endothelial cell density, a measure of corneal health, remained above the safe threshold in 98.5% of cases over the follow-up period, declining at an average rate of about 1.1% per year.
The most common reason for a lens to be exchanged or removed is improper vault size. “Vault” refers to the gap between the implanted lens and your natural lens. If the vault is too small, the ICL can press against your natural lens and promote cataract growth. If it’s too large, it can push the iris forward and raise eye pressure. In one study, vault issues accounted for roughly 69% of all exchanges or removals, followed by cataract formation (about 13%) and elevated eye pressure (about 9%).
Reversibility
One of EVO ICL’s most appealing features is that it’s fully reversible. Unlike LASIK, which permanently removes corneal tissue, the ICL can be surgically removed if your needs change. If your prescription shifts significantly, the lens can be exchanged for a different power. If you develop cataracts later in life, the lens is removed during the cataract procedure and replaced with an intraocular lens, just as it would be for anyone else having cataract surgery. Your cornea remains in its original state throughout all of this.
Cost
EVO ICL typically costs between $3,000 and $5,000 per eye in the United States, making it more expensive than LASIK for most patients. The price varies based on your location, the surgeon’s experience, whether you need the toric version for astigmatism, and what the practice includes in its pricing (some bundle all follow-up visits and warranties, others don’t). Because it’s considered an elective procedure, routine vision insurance and medical insurance generally do not cover it. Many practices offer financing plans to spread the cost over time.